jasdooit

Therapex, a local biotechnology firm, has handed over the technology for TRX-211, a new non-small cell lung cancer (NSCLC) drug candidate that was created internally, to Huons.

Huons reported on the 23rd that it has entered into an agreement to bring TRX-211, a specific anticancer drug for non-small cell lung cancer, NSCLC, developed by Therapex, into its portfolio, thus broadening its research and development pipeline.

According to the agreement, the company will take charge of the clinical development of TRX-211, which is currently in the preclinical phase, and will own the domestic rights once it is approved. Additionally, it has the possibility to acquire global distribution rights at a later date.

TRX-211 is an orally administered tyrosine kinase inhibitor (TKI) designed to target the EGFR Exon20 insertion mutation in non-small cell lung cancer, NSCLC. Lung cancer is categorized as small cell lung cancer when the cancer cells are smaller in size, and as non-small cell lung cancer when the cells are larger.

Huons launched TRX-211, expecting it to offer a novel treatment option for patients suffering from EGFR Exon20 insertion mutation NSCLC, who urgently require new therapeutic choices.

Therapex’s CEO Lee Koo stated, “TRX-211 is an innovative drug candidate that reflects Therapex’s expertise in treating non-small cell lung cancer with EGFR mutations. We aim to introduce a new approach where a technology-driven biotech company evolves into a commercial entity by effectively leveraging Huons’ strong research and development infrastructure and clinical network.”

Huons’ CEO Song Soo-young said, “This represents an open innovation approach where Huons’ extensive global clinical and commercialization expertise is integrated with Therapex’s cutting-edge targeted cancer treatment technology. In the future, we aim to develop Huons’ distinctive synergy in the creation of new medications by fully adopting long-term goals and external technologies.”